AWM GPW Periodic report · PAP Biznes
Airway Medix SA (AWM) · Q1 2026 results
Share price: 0.24 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 25 May 2026 and 30 May 2025
Net loss widened year on year. The report's language is unchanged.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2025
Net income -1.5M vs -1.1M
2 · How the report reads
Unchanged
Language tone vs last period
Report language: restrained for a company report — about as upbeat as in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Fading
Subscription agreements for series H and I shares were concluded on April 8, 2025, and April 24, 2025, for a total nominal value of 6,161,439.88.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
0.24 zł
close of 2026-11-10
P/E
12.1
today
Revenue growth, 3 years
−65.2% a year
compound annual rate (CAGR)
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Restrained for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“Decreased or lack of demand for these products, and more broadly for the innovative solutions offered by the Group, may cause a decline in the value of projects conducted by the Group as well as problems with their commercialization.”
“Unexpected difficulties in change management or any inability of the Group to manage growth may have a significant adverse impact on its strategy.”
“There is therefore a risk that these objectives will not be met, and consequently, the fees received by the Group will be lower than expected or equal to zero.”
Full figures
PLN · PAP Biznes report (2026-05-25)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 85.0K | 0 | |
| Operating income | -1.5M | -1.1M | Loss widened |
| Net income | -1.5M | -1.1M | Loss widened |
| EPS | -0.01 | -0.01 | ±0% |
| P/E today 12.1 | 14.6 | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Certification covers, among others, product design and development processes, production and sale of medical devices, and obtaining the…
- Fading The Management Board of the Company adopted a resolution to increase the Company's share capital within the limits of the target capital…
- However, it cannot be entirely ruled out that the Group will not be able to develop and expand its portfolio with further projects with…
- Until the decision is issued, there is therefore a risk associated with the refusal to grant patent protection or granting it in a scope…
- In these interim condensed consolidated financial statements, the significant judgments made by the Management regarding the accounting…
Faded since Q1 2025
- Fading As part of the target capital and the establishment of the consolidated text including these changes, c.
- Fading The carrying amount of the receivables is close to their fair value.
- Fading Airway Medix plans to start pilot sales and the proper launch of the product in the EU and outside the EU for two products from the…
Latest announcements
Official filings, newest first.
- Rezygnacja Członka Rady Nadzorczej. · ESPI 21/2026
- Half-year report · ESPI periodic
- Informacje przekazane na podstawie art. 19 ust. 3 Rozporządzenia MAR · ESPI 20/2026
- Aktualizacja informacji nt. procesu certyfikacyjnego ISO 13485. · ESPI 19/2026
- Informacja o konwersji wierzytelności obligacyjnych wobec Adiuvo Investments S.A. na akcje. · ESPI 18/2026
- Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Airway Medix S.A. w dniu 26 czerwca 2026 r. · ESPI 17/2026
- Rezygnacja Prezesa Zarządu w Airway Medix S.A. · ESPI 16/2026
- Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Airway Medix S.A. · ESPI 15/2026